Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 1/20 | 0.62 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.61 |
| ▸ | REN | P00797 | 2/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | APEX1 | P27695 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10032155 | 0.92 | CNR2 (0.73) | CNR2LTB4R2REN | |
| SCHEMBL19405101 | 0.89 | TDP1 (0.69) | CNR2LTB4R2RENPOLBAPEX1 | |
| SCHEMBL13494187 | 0.85 | CNR2 (0.62) | CNR2LTB4R2RENPOLBAPEX1 | |
| SCHEMBL11164236 | 0.83 | CNR2 (0.50) | CNR2LTB4R2RENCYP1A2CYP3A4 | |
| SCHEMBL22566158 | 0.82 | MC3R (0.58) | CNR2REN | |
| SCHEMBL3631071 | 0.82 | POLB (0.60) | CNR2LTB4R2RENPOLBAPEX1 | |
| SCHEMBL195224 | 0.81 | LMNA (0.58) | CNR2REN | |
| SCHEMBL2721394 | 0.81 | REN (0.69) | CNR2LTB4R2RENPOLBAPEX1 | |
| SCHEMBL14229143 | 0.80 | CA12 (0.57) | LTB4R2TDP1 | |
| SCHEMBL1753870 | 0.80 | HDAC6 (0.58) | CNR2LTB4R2RENGAAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200131335-A1 | SURFACE ACTIVE ADJUVANT | RHODIA OPERATIONS (FR) | 2020-04-30 | — | — | US | disclosed |
| US-8822720-B2 | Method for the organocatalytic activation of carboxylic acids for chemical, reactions using orthosubstituted arylboronic acids | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2014-09-02 | — | — | US | disclosed |
| US-8822720-B2 | Method for the organocatalytic activation of carboxylic acids for chemical, reactions using orthosubstituted arylboronic acids | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2014-09-02 | — | — | US | disclosed |
| US-20100197960-A1 | METHOD FOR THE ORGANOCATALYTIC ACTIVATION OF CARBOXYLIC ACIDS FOR CHEMICAL, REACTIONS USING ORTHOSUBSTITUTED ARYLBORONIC ACIDS | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2010-08-05 | — | — | US | disclosed |
| US-20100197960-A1 | METHOD FOR THE ORGANOCATALYTIC ACTIVATION OF CARBOXYLIC ACIDS FOR CHEMICAL, REACTIONS USING ORTHOSUBSTITUTED ARYLBORONIC ACIDS | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2010-08-05 | — | — | US | disclosed |
| US-5328884-A | Salicylic acid salt,and amide or sulfonamide as developer | KANZAKI PAPER MANUFACTURING CO., LTD. (JP) | 1994-07-12 | — | — | US | disclosed |
| US-5250108-A | Mixture of salicylic acid salt, amide and sulfonamide compounds | KANZAKI PAPER MANUFACTURING CO. LTD. (JP) | 1993-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197960-A1 | METHOD FOR THE ORGANOCATALYTIC ACTIVATION OF CARBOXYLIC ACIDS FOR CHEMICAL, REACTIONS USING ORTHOSUBSTITUTED ARYLBORONIC ACIDS | AOC2, AOC3, OXER1 | CNR2 1776/4885LTB4R2 1007/4885REN 1219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.